Sleep Medicine Reviews
Volume 4, Issue 6 , Pages 551-581 , December 2000

Non-benzodiazepines for the treatment of insomnia

  • Judy Wagner

      Affiliations

    • Department of Clinical Practices and Therapeutics, Merck-Medco-Managed Care, L.L.C. Franklin Lakes, NJ, USA
    • ,
  • Mary L. Wagner

      Affiliations

    • Department of Pharmacy Practice, Rutgers, The State University of New Jersey, College of Pharmacy, Piscataway, NJ, USA

References 

  1. Rosekind MR. The epidemiology and occurrence of insomnia. J Clin Psychiatry. 1992;53 (Suppl. 6):4–6
  2. Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16:873–897
  3. Maczaj M. Pharmacological treatment of insomnia. Drugs. 1993;45:44–55
  4. Kupfer DJ, Reynolds CF. Management of insomnia. NEJM. 1997;336:341–346
  5. Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs: a review. PsychoÍpharmacology. 1996;126:1–16
  6. Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs. 1994;48:25–40
  7. Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology. 1995;51:205–223
  8. Rumack, BH, Bird, PE, Gelman, CR, DrugDex System. (eds). Micromedex Inc. Engelwood, CO. Edition expires 5/31/2000
  9. Hartmann E. Nightmares and other dreams. In Kryger MH, Roth T, Dement WC (eds). Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Co. 1994;407–410
  10. Short TG, Galletly DC. Double-blind comparison of midazolam and triazolam as oral premedicants for outpatient anaesthesia. Anaesth Intensive Care. 1989;17:151–156
  11. Mendelson WB, Jain B. An assessment of short-acting hypnotics. Drug Saf. 1995;15:257–270
  12. Bunney WE, Azarnoff DL, Brown BW. Report of the Institute of Medicine Committee on the efficacy and safety of Halcion. Arch Gen Psychiatry. 1999;56:349–352
  13. Halcion . [package insert]. Kalamazoo, MI: Upjohn Co. 1999;
  14. Mamelak M, Csima A, Price V. The effects of a single night's dosing with triazolam on sleep the following night. Clin Pharmacol. 1990;30:549–555
  15. Jermain DM. Sleep disorders. In Dipiro JT, Talbert RL, Yee GC et al. (eds). Pharmacotherapy: A Pathophysiologic Approach, 4th Edition. Stamford: Appleton and Lange. 1999;1208–1218
  16. Cohn MA. Hypnotics and the control of breathing: a review. Br J Clin Pharmacol. 1983;16 (Suppl. 2):245–250
  17. Guilleminault C. Benzodiazepines, breathing, and sleep. Am J Med. 1990;88 (Suppl. 3A):25–28
  18. Mendelson WB, Garnett D, Gillin JC. Flurazepam-induced sleep apnea syndrome in a patient with insomnia and mild sleep-related respiratory changes. J Nerv Ment Dis. 1981;4:261–264
  19. Dolly FR, Block AJ. Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic subjects. Am J Med. 1982;73:239–243
  20. Clark TJ, Collins JV, Tong D. Respiratory depression caused by nitrazepam in patients with respiratory failure. Lancet. 1971;ii:737–738
  21. Model DG. Nitrazepam induced respiratory depression in chronic obstructive lung disease. Br J Dis Chest. 1973;67:128–130
  22. Sanger DJ, Zivkovic B. Differential development of tolerance to the depressant effects of benzodiazepine and non-benzodiazepine agonists at the omega (BZ) modulatory sites of GABAAreceptors. Neuropharmacology. 1992;31:693–700
  23. Sanger DJ, Benavides J, Perrault G. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev. 1994;18:355–372
  24. Wamsley JK, Hunt ME. Relative affinity of quazepam for type-1 benzodiazepine receptors in brain. J Clin Psychiatry. 1991;52 (Suppl. 9):15–20
  25. Hoehns JD, Perry PJ. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm. 1993;12:814–828
  26. Greenblatt DJ, Harmatz JS, von Moltke LL. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther. 1998;64:553–561
  27. Vanover KE, Mangano RM, Barrett JE. Cl 284,846, novel sedative–hypnotic: evaluation of its metabolites for pharmacological activity in vitro and in vivo. Drug Dev Res. 1994;33:39–45
  28. Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs. 1998;55:277–302
  29. Mitler MM. Non-selective and selective benzodiazepine agonists—where are we today?. Sleep. 2000;23 (Suppl. 1):39–47
  30. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59:1–25
  31. Lahmeyer H, Wilcox CS, Kann J. Subjective efficacy of zolpidem in outpatients with chronic insomnia: a double-blind comparison with placebo. Clin Drug Invest. 1997;13:134–144
  32. Scharf MB, Roth T, Vogel GW. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192–199
  33. Monti JM. Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol. 1989;36:461–466
  34. Kryger MH, Steljes D, Pouliot Z. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep. 1991;14:399–407
  35. Roth R, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995;18:246–251
  36. Monti JM, Attali P, Monti D. Zolpidem and rebound insomnia—a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry. 1994;27:166–175
  37. Blois R, Gaillard J, Attali P. Effect of zolpidem on sleep in healthy subjects: a placebo-controlled trial with polysomnographic recordings. Clin Ther. 1993;15:797–809
  38. Herrmann WM, Kubicki ST, Boden S. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic ««learned»» insomnia: psychometric and polysomnographic evaluation. J Int Med Res. 1993;21:306–322
  39. Girault C, Muir J, Mihaltan F. Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD. Chest. 1996;110:1203–1211
  40. Besset A, Tafti M, Villemin E. Effects of zolpidem on the architecture and cyclical structure of sleep in poor sleepers. Drugs Exp Clin Res. 1995;21:161–169
  41. Ware JC, Walsh JK, Scharf MB. Minimal rebound insomnia after treatment with 10 mg zolpidem. Clin Neuropharm. 1997;20:116–125
  42. Steens RD, Pouliot Z, Millar TW. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep. 1993;16:318–326
  43. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther. 1993;15:127–136
  44. Pagot R, Cramer P, L»Heritier C. Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients. Curr Ther Res. 1993;53:88–97
  45. Lovel E, Cramer P, Ferreri M. Zolpidem and triazolam: long term multicenter studies (1–3 months) in psychiatric and general practice patients. In Sauvanet JP, Langer SZ, Morselli PL (eds). Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. New York: Raven Press. 1988;327–337
  46. Rosenberg J, Ahlstrøm F. Randomized, double-blind trial of zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice. Scand J Prim Health Care. 1994;12:88–92
  47. Sicard BA, Trocherie S, Moreau J. Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel and pilots. Aviat Space Environ Med. 1993;64:371–375
  48. Berlin I, Warot D, Hergueta T. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol. 1993;13:100–106
  49. Wesensten NJ, Balkin TJ, Belenkey GL. Effects of daytime administration of zolpidem and triazolam on performance. Aviat Space Environ Med. 1996;67:115–120
  50. Mintzer MZ, Frey JM, Yingling JE. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol. 1997;8:561–574
  51. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol. 1992;43:597–601
  52. Bensimon G, Foret J, Warot D. Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo. Br J Clin Pharmacol. 1990;30:463–469
  53. Fleming J, Moldofsky H, Walsh JK. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin Drug Invest. 1995;9:303–313
  54. Frattola L, Maggioni M, Cesana B. Double blind comparison of zolpiden 20 mg versus flunitrazepam 2 mg in insomniac in-patients. Drugs Exper Clin Res. 1990;16:371–376
  55. Scharf MD, Roth T, Vogel G. A multicenter placebo controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192–199
  56. Erman M, Erwin C, Gengo F. Efficacy of zolpidem and temazepam in transient insomnia [abstract]. Abstracts of the proceedings of the 9thAnnual Meeting of Associated Professional Sleep Societies (APSS), Nashville, TN, USA, 30 May–4 June. 1995;15:8
  57. Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol. 1996;16:146–157
  58. Balkin TS, O»Donnell VM, Wesensten N. Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology. 1992;107:83–88
  59. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res. 1992;20:150–161
  60. Allain H, Patat A, Lieury A. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry. 1995;10 (Suppl. 3):129–135
  61. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol. 1995;48:115–122
  62. Roehrs T, Merlotti L, Zorick F. Sedative, memory, and performance effects of hypnotics. Psychopharmacology. 1994;116:130–134
  63. Unden M, Schechter BR. Next day effects after nighttime treatment with zolpidem: a review. Eur Psychiatry. 1996;11 (Suppl. 1):21–30
  64. Monti JM, Monti D, Estevez F. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol. 1996;11:255–263
  65. Schlich D, L»Heritier CL, Coquelin JP. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res. 1991;19:271–279
  66. Maarek L, Cramer P, Attali P. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res. 1992;20:162–170
  67. Elie R, Rüther E, Farr I. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry. 1999;60:536–544
  68. Fry J, Scharf MB, Berkowitz DV. A phase III, 28 day, multicenter, randomized, double-blind, comparator and placebo-controlled, parallel-group safety, tolerability, and efficacy study of 5, 10, and 20 mg of zaleplon, compared with 10 mg of zolpidem or placebo, in adult outpatients with insomnia [abstract]. Sleep. 1998;21 (Suppl.):262
  69. Ancoli-Israel S, Walsh JK, Mangano RM. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Primary Care Companion J Clin Psychiatry. 1999;1:114–120
  70. Silvestri R, Ferillo F, Murri L. Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomized comparison of zolpidem versus triazolam. Hum Psychopharmacol. 1996;11:225–233
  71. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol. 1999;14:287–303
  72. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16 944 cases. Int Clin Psychopharmacol. 1998;13:157–167
  73. Cavallaro R, Regazzetti MG, Covelli G. Tolerance and withdrawal with zolpidem [letter]. Lancet. 1993;342:374–375
  74. Sánchez LGB, Sanchez JM, Moreno JLL. Dependence and tolerance with zolpidem [letter]. Am J Health Syst Pharm. 1996;53:2638
  75. Allain H, Le Coz F, Borderies P. Use of zolpidem 10 mg as a benzodiazepine substitute in 84 patients with insomnia. Hum Psychopharmacol. 1998;13:551–559
  76. Genton P, Blin O, Borderies P. Substitution of chronic flunitrazepam by placebo or zolpidem: a multicentric, double-blind, parallel-group study [abstract]. J Sleep Res. 1994;3 (Suppl. 1):561
  77. Kummer J, Guendel L, Linden J. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res. 1993;21:171–184
  78. Sanger DJ, Zivkovic B. Investigation of the development of tolerance to the actions of zolpidem and midazolam. Neuropharmacology. 1987;26:1513–1518
  79. Sanger DJ. Further investigation of the stimulus properties of chlordiazepoxide and zolpidem. Agonism and antagonism by two novel benzodiazepines. Psychopharmacology. 1987;93:365–368
  80. Griffiths RR, Sannerud CS, Ator N. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther. 1992;260:1199–1208
  81. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther. 1990;255:1246–1255
  82. Rush CR, Baker RW, Wright K. Acute behavioral and abuse potential of trazodone, zolpidem, and triazolam in humans. Psychopharmacology. 1999;144:220–233
  83. Gericke CA, Ludolph AC. Chronic abuse of zolpidem [letter]. JAMA. 1994;272:1721–1722
  84. Cluydts R, Peeters K, De Bouyalsky I. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res. 1998;26:13–24
  85. Ganzoni E, Santoni JP, Chevillard V. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J Int Med Res. 1995;23:61–73
  86. Markowitz JS, Rames LJ, Reeves N. Zolpidem and hallucinations [letter]. Ann Emerg Med. 1997;29:300–301
  87. Ansseau M, Pitchot W, Hansenne M. Psychotic reactions to zolpidem [letter]. Lancet. 1992;339:809
  88. Pies RW. Dose-related sensory distortions with zolpidem [letter]. J Clin Psychiatry. 1995;56:35–36
  89. Murciano D, Armengaud MH, Cramer PH. Acute effects of zolpidem, triazolam and flunitrazepam on arterial blood gases and control of breathing in severe COPD. Eur Respir J. 1993;6:625–629
  90. Murciano D, Aubier M, Palacios S. Comparison of zolpidem, triazolam, and flunitrazepam effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD). Chest. 1990;97 (Suppl. 3):51–52
  91. Cirignotta F, Mondini S, Zucconi M. Zolpidem-polysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome. Pharmacol Biochem Behav. 1988;29:807–809
  92. Quera-Salva MA, McCann C, Boudet J. Effects of zolpidem on sleep architecture, night time ventilation, daytime vigilance and performance in heavy snorers. Br J Clin Pharmacol. 1994;37:539–543
  93. Polks DG, Burke WJ. Sedative hypnotics and sleep. Clin Geriatric Med. 1998;14:67–85
  94. Wadworth AN, McTavish D. Zopiclone: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging. 1993;3:441–459
  95. Goa KL, Heel RC. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs. 1986;32:48–65
  96. Autret E, Maillard F, Autret A. Comparison of the clinical hypnotic effects of zopiclone and triazolam. Eur J Clin Pharmacol. 1987;31:621–623
  97. Chaudoir PJ, Bodkin NL, O»Donnell . A comparative study of zopiclone and triazolam in patients with insomnia. Int Clin Psychopharmacol. 1990;5 (Suppl. 2):21–27
  98. Elie R, Frenay M, Le Morvan P. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol. 1990;5 (Suppl. 2):39–46
  99. Hajak G, Clarenbach P, Fischer W. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol. 1994;9:251–261
  100. Fleming JA, McClure DJ, Mayes C. A comparison of the efficacy, safety, and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol. 1990;5 (Suppl. 2):29–37
  101. Ngen CC, Hassan R. A double-blind, placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. Int Clin Psychopharmacol. 1990;5:165–171
  102. van der Kleijn E. Effects of zopiclone and temazepam on sleep, behaviour, and mood during the day. Eur J Clin Pharmacol. 1989;36:247–251
  103. Ponciano E, Freitas F, Camara J. A comparison of the efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac outpatients. Int Clin PsychoÍpharmacol. 1990;5 (Suppl. 2):69–77
  104. Elie R, Lavoie G, Bourgouin J. Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Pcyhopharmacol. 1990;5:279–286
  105. Agnoli A, Manna V, Martucci N. Double-blind study on the hypnotic and anti-anxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia. Int J Clin Pharm Res. 1989;10:277–281
  106. Anderson AA. Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice. Sleep. 1987;10 (Suppl. 1):54–62
  107. Klimm HD, Dreyfus JF, Delmotte M. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. Sleep. 1987;10 (Suppl. 1):73–78
  108. Tamminen T, Hansen PP. Chronic administration of zopiclone and nitrazepam in the treatment of insomnia. Sleep. 1987;10 (Suppl. 1):63–72
  109. Wikstrom E, Gotlibsen OB, Bredesen . Performance and mood following partial sleep deprivation: a randomized, double-blind, cross-over study of zopiclone, triazolam, flunitrazepam, ethanol, and placebo. Hum Psychopharmacol. 1988;3:3–11
  110. Hindmarch I. Immediate and overnight effects of zopiclone 7.5 mg and nitrazepam 5 mg with ethanol on psychomotor performance and memory in healthy volunteer. Int Clin Psychopharmacol. 1990;5 (Suppl. 2):105–113
  111. Nicholson AN, Stone BM. Efficacy of zopiclone in middle age. Sleep. 1987;10 (Suppl. 1):35–39
  112. Warot D, Bensimon G, Danjou . Comparative effects of zopiclone, triazolam, and placebo on memory and psychomotor performance in healthy volunteers. Fundam Clin Pharmacol. 1987;1:145–152
  113. Mamelak M, Buck L, Csima A. Effects of flurazepam and zopiclone on the performance of chronic insomniac patients: a study of ethanol–drug interaction. Sleep. 1987;10 (Suppl. 1):79–87
  114. Lader M, Denney SC. A double-blind study to establish the residual effects of zopiclone on performance in healthy volunteers. Int Pharmacopsychiatry. 1982;17 (Suppl. 1):98–108
  115. Billiard M, Besset A, de Lustrac C. Dose response effects of zopiclone on night sleep and on nighttime and daytime functioning. Sleep. 1987;10 (Suppl. 1):27–34
  116. Nicholson AN, Stone BM. Zopiclone: sleep and performance studies in healthy man. Int Pharmacopsychiatry. 1982;17 (Suppl. 2):92–97
  117. Vermeeren A, Danjou PE, O»Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol. 1998;13 (Suppl. 2):98–107
  118. Fossen A, Godlibsen OB, Loyning Y. Effects of hypnotics on memory. Pharmacology. 1983;27 (Suppl. 2):116–126
  119. Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol. 1990;5 (Suppl. 2):139–145
  120. Pecknold J, Wilson R, Le Morvan P. Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol. 1990;5 (Suppl. 2):57–67
  121. Begg EJ, Robson RA, Frampton CM. A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone. N Z Med J. 1992;105:428–429
  122. Lader M. Zopiclone: is there any dependence and abuse potential?. J Neurol. 1997;244 (Suppl. 1):18–22
  123. Mouret J, Ruel D, Maillard F. Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol. 1990;5 (Suppl. 2):47–55
  124. Lader M. Rebound insomnia and newer hypnotics. Psychopharmacology. 1992;108:248–255
  125. Inman W, Kubota K, Pearce G. PEM report number 10: zopiclone. Pharmacoepidemiol Drug Saf. 1993;2:499–521
  126. Jones IR, Sullivan G. Physical dependence on zopiclone: case reports [letter]. BMJ. 1998;316:117
  127. Sikdar S, Ruben SM. Zopiclone abuse among polydrug users [letter]. Addiction. 1996;91:285–286
  128. Ayonrinde O, Sampson E. Physical dependence on zopiclone. Risk of dependence may be greater in those with dependent personalities [letter]. BMJ. 1998;317:146
  129. Pat-Horenczyk R, Hacohen D, Herer P. The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology. 1998;140:450–457
  130. Shapiro CM, Sherman D, Peck DF. Withdrawal from benzodiazepines by initially switching to zopiclone. Eur Psychiatry. 1995;10 (Suppl. 3):145–151
  131. Fleming JA, Bourgouin J, Hamilton P. A sleep laboratory evaluation of the long-term efficacy of zopiclone. Can J Psychiatry. 1988;33:103–107
  132. Allain H, Delahaye C, Le Coz F. Postmarketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. Sleep. 1991;14:408–413
  133. Muir JF, Defouilloy C, Broussier P. Comparative study of the effects of zopiclone and placebo on respiratory function in patients with chronic obstructive respiratory insufficiency. Int Clin Psychopharmacol. 1990;5 (Suppl. 2):85–94
  134. Beaupre A, Soucy R, Phillips R. Respiratory center output following zopiclone or diazepam administration in patients with pulmonary disease. Respiration. 1988;54:235–240
  135. Lofaso F, Goldenberg F, Thebault C. Effect of zopiclone on sleep, night-time ventilation, and daytime vigilance in upper airway resistance syndrome. Eur Respir J. 1997;10:2573–2577
  136. Allen D, Curran HV, Lader M. The effects of single doses of CL 284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol. 1993;45:313–320
  137. Walsh JK, Fry J, Erwin CW. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest. 1998;16:347–354
  138. Walsh JK, Vogel GW, Scharf . A five week polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med. 2000;1:41–49
  139. Hedner J, Emilien G, Salinas E. Improvement in sleep latency and sleep quality with zaleplon in elderly patients with primary insomnia [abstract]. J Sleep Res. 1998;7 (Suppl. 2):115
  140. Roth, T, Roehrs, TA, Fortier, J, Dose response effects of a new hypnotic in insomniacs [abstract], Abstracts of the proceedings of the 9thAnnual Meeting of Associated Professional Sleep Societies (APSS), Nashville, TN, USA, 30 May–4 June, 15, 30
  141. Sonata . [package insert]. Philadelphia, PA: Wyeth Laboratories. 1999;
  142. Darwish, M, Danjou, P, Paty, I, Overall peak psychomotor and memory effects of zaleplon in clinical pharmacology studies, Poster presented at the 21stCongress Collegium Internationale Neuropsychologicum (CINP); July 12–16, 1998; Glasgow, Scotland
  143. Walsh JK, Scharf MB, Pollak C. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia [abstract]. Sleep. 1998;21 (Suppl.):247
  144. Dietrich B, Emilien G, Salinas E. Zaleplon does not produce residual sedation in a phase-advance model of transient insomnia [abstract]. J Sleep Res. 1998;7 (Suppl. 2):67
  145. Danjou P, Paty I, Fruncillo R. A comparison of the residual effects of zaleplon and zolpidem following administrations 5 to 2 h before awakening. Br J Clin Pharmacol. 1999;48:367–374
  146. Scharf M. The safety of long-term treatment of insomnia with zaleplon [abstract]. J Eur Coll Neuropsych. 1999;9 (Suppl. 5):360
  147. Rush CR, Frey JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology. 1999;145:39–51
  148. George CFP, Series F, Kryger , Moskovitch A. Safety and efficacy of zaleplon versus zolpidem in outpatients with chronic obstructive pulmonary disease (COPD) and insomnia [abstract]. Sleep. 1999;22 (Suppl.):320

☆ Correspondence should be addressed to: Mary L. Wagner, MS, PharmD, Associate Professor, Department of Pharmacy Practice, Rutgers, The State University of New Jersey. College of Pharmacy, 160 Frelinghuysen Road, Busch Campus, Piscataway, NJ, 88854, USA. Fax: (732) 445-2533; E-mail: mwagner@cop.rutgers.edu

PII: S1087-0792(00)90126-6

doi: 10.1053/smrv.2000.0126

Sleep Medicine Reviews
Volume 4, Issue 6 , Pages 551-581 , December 2000

Article Tools